Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme

References

• Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. J Clin Exp Psychopathol 1959; 20: 53–57
   PubMedGoogle Scholar
• Robinson RG, McHugh PR, Folstein MF. Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 1975; 12: 59–68
   PubMed Web of Science ®Google Scholar
• Freedman R. Schizophrenia. N Engl J Med 2003; 349: 1738–1749
   PubMed Web of Science ®Google Scholar
• Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005; 50 (Suppl 1):7S–57S.
   PubMedGoogle Scholar
• Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7(Suppl 3)5–69
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223
   PubMed Web of Science ®Google Scholar
• Stedman T, Welham J. The distribution of adipose tissue in female in-patients receiving psychotropic drugs. Br J Psychiatry 1993; 162: 249–250
   PubMed Web of Science ®Google Scholar
• Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001; 158: 1719–1722
   PubMed Web of Science ®Google Scholar
• Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565–567
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic non-compliance. Schizophr Res 2004; 66: 51–57
   PubMed Web of Science ®Google Scholar
• Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotic: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537–551
   PubMed Web of Science ®Google Scholar
• Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62(Suppl 7)22–31
   PubMed Web of Science ®Google Scholar
• Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205–219
   PubMed Web of Science ®Google Scholar
• Baptista T, Zarate J, Joober R et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics Curr Drug Targets 2004; 5:279–299.
   PubMed Web of Science ®Google Scholar
• Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000; 101: 416–432
   PubMed Web of Science ®Google Scholar
• Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001; 24: 59–73
   PubMed Web of Science ®Google Scholar
• Wirshing DA , Wirshing WC , Kysar L et al . Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60:358–363.
   PubMed Web of Science ®Google Scholar
• Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193–220
   PubMed Web of Science ®Google Scholar
• Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28(Suppl 1)83–96
   PubMed Web of Science ®Google Scholar
• Tardieu S, Micallef J, Gentile S, Blin O. Weight gain profiles of new anti-psychotics: public health consequences. Obes Rev 2003; 4: 129–138
   PubMedGoogle Scholar
• Consensus statement, consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596–601.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004; 74: 1999–2008
   PubMed Web of Science ®Google Scholar
• Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26: 137–141
   PubMed Web of Science ®Google Scholar
• Martin A , Landau J , Leebens P et al . Risperidone-associated weight gain in children and adolescents: a retrospective chart review J Am Acad Child Adolesc Psychiatry 2000; 10:259–268.
   Google Scholar
• Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001; 62(Suppl 2)41–44
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92–100
   PubMed Web of Science ®Google Scholar
• Henderson DC , Cagliero E , Gray C et al . Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study Am J Psychiatry 2000; 157:975–981.
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Putting metabolic side effects into perspective: risk versus benefits of atypical antipsychotics. J Clin Psychiatry 2001; 62(Suppl 27)35–39
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Muroff M, Gibson PJ, Grainger D. Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr Bull 2002; 28: 619–635
   PubMed Web of Science ®Google Scholar
• Poulin MJ, Cortese L, Williams R, Wine N, McIntyre R. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can J Psychiatry 2005; 50: 555–562
   PubMed Web of Science ®Google Scholar
• Fox R, Rotatori AF, Wicks A. Weight loss with psychiatric residents in a behavioral self-control program. Psychol Rep 1980; 46: 483–486
   PubMed Web of Science ®Google Scholar
• Knox JM. A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry 1980; 136: 287–289
   PubMed Web of Science ®Google Scholar
• Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv 2001; 52: 967–969
   PubMed Web of Science ®Google Scholar
• Cazenave M, Gershon S, Sletten IW. Effects of caloric restriction on behavior and body weight during chlorpromazine therapy. Dis Nerv Syst 1967; 28: 519–522
   PubMedGoogle Scholar
• Keck PE, Buse J, Dagogo JS, et al. Managing metabolic concerns in patients with severe mental illness. McGraw Hill Healthcare Information Group, Edina, MN 2003
   Google Scholar
• Richardson CR, Faulkner G, McDevitt J, Skrinar GS, Hutchinson DS, Piette JD. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv 2005; 56: 324–331
   PubMed Web of Science ®Google Scholar
• Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003; 108: 324–332
   PubMed Web of Science ®Google Scholar
• Centorrino F, Wurtman JJ, Duca KA, et al. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes 2006; 30: 1011–1016\
   PubMed Web of Science ®Google Scholar
• Aquila R, Emanuel M. Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Comp J Clin Psychiatry 2000; 2: 20–23
   PubMedGoogle Scholar
• Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004; 65: 471–477
   PubMed Web of Science ®Google Scholar
• Pendlebury J, Haddad P, Dursun S. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 2005; 20: 447–448
   PubMed Web of Science ®Google Scholar
• Government of Canada . Canada's food guide to healthy eating (online). Ottawa: Health Canada, 2005. [Accessed 25 May 2007.] Available from URL: http://www.hc-sc.gc.ca/hpfb-dgpsa/onpp-bppn/food_guide_rainbow_c.html.
   Google Scholar
• Airlie (VA) Consensus Conference . Standardization of anthropometric measurements. Champaign, IL: Human Kinetics Publishers, 1988.
   Google Scholar
• Couillard C , Després JP , Lamarche B et al . Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001; 21:1226–1232.
   PubMed Web of Science ®Google Scholar
• Richterich R, Dauwalder H. Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method. Schweiz Med Wochenschr 1971; 101: 615–618
   PubMedGoogle Scholar
• Guy W. Clinical global impressions. ECDEU assessment manual for psychopharmacology, US Dept Health, Education and Welfare publication (ADM) 76–338. Rockville, MD: National Institute of Mental Health, 1976.
   Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799–812
   Web of Science ®Google Scholar
• Manocchia M, Bayliss MS, Connor J, et al. SF-36 health survey annotated bibliographysecond edition. Health Assessment Lab, New England Medical Center, Boston, MA 1988; 1998
   Google Scholar
• Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1495–1507
   Web of Science ®Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . JAMA 2001; 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812–819
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D'Agostino RB, Levy D, Bélanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847
   PubMed Web of Science ®Google Scholar
• Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatr 2001; 62: 231–238
   PubMed Web of Science ®Google Scholar
• Craft LL, Landers DM. The effect of exercise on clinical depression and depression resulting from mental illness: a meta-analysis. J Sports Exerc Psychol 1998; 20: 339–357
   Web of Science ®Google Scholar
• Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ 2001; 322: 763–767
   PubMed Web of Science ®Google Scholar
• Faulkner G, Biddle S. Exercise as an adjunct treatment for schizophrenia: a review of the literature. J Ment Health 1999; 8: 441–457
   Google Scholar
• Martinsen E. The effects of exercise on mental health in clinical populations. European perspectives on exercise and sport psychology, S Biddle. Human Kinetics, StanningleyUK 1995; 185–211
   Google Scholar
• O'Kelly JG, Piper WE, Kerber R, Fowler J. Exercise groups in an insight-oriented, evening treatment program. Int J Group Psychother 1998; 48: 85–98
   PubMed Web of Science ®Google Scholar
• Brown S, Birtwistle J, Roe L, Thomson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697–701
   PubMed Web of Science ®Google Scholar
• Davidson S, Judd F, Jolley D, Hocking B, Thomson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001; 35: 196–202
   PubMed Web of Science ®Google Scholar
• Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62: 486–491
   PubMed Web of Science ®Google Scholar
• Anthony W, Cohen M, Farkas M. Psychiatric rehabilitation. Center for Psychiatric Rehabilitation, Boston, MA 2002
   Google Scholar
• Richardson CR, Faulkner G, McDevitt J, Skrinar GS, Hutchinson DS, Piette JD. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv 2005; 56: 324–331
   PubMed Web of Science ®Google Scholar
• Tremblay A, Doucet E. Obesity: a disease or a biological adaptation?. Obes Rev 2000; 1: 27–35
   PubMedGoogle Scholar